{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:37:58Z","timestamp":1793882278229,"version":"4.7.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.eururo.2022.07.023","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T08:04:50Z","timestamp":1660205090000},"page":"313-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-6676","authenticated-orcid":false,"given":"Alberto","family":"Gil-Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"van Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Contreras-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristan","family":"van der Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde","family":"Braaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegien","family":"Broeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Kerkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.M.","family":"van Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Ribal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk F.A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.07.023_b0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.023_b0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.023_b0015","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2022.07.023_b0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.023_b0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","article-title":"ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.07.023_b0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.023_b0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2022.07.023_b0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.023_b0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.07.023_b0050","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2023.03.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822025386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822025386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:10:59Z","timestamp":1708459859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822025386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0302283822025386"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.07.023","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}